Biocon Limited announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (6mg/ml solution for injection in pre-filled pen), which was filed through its European partner, Zentiva. Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus, a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
308.7 INR | +3.40% | +9.99% | +23.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.43% | 4.27B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K